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Research Paper
Peripheral inflammatory pain sensitisation is
independent of mast cell activation in male mice
Douglas M. Lopes*, Franziska Denk, Kim I. Chisholm, Tesha Suddason, Camille Durrieux, Matthew Thakur,
Clive Gentry, Stephen B. McMahon
Abstract
The immune and sensory systems are known for their close proximity and interaction. Indeed, in a variety of pain states, a myriad of
different immune cells are activated and recruited, playing a key role in neuronal sensitisation. During inflammatory pain it is thought
that mast cells (MC) are one of the immune cell types involved in this process, but so far the evidence outlining their direct effect on
neuronal cells remains unclear. To clarify whether MC are involved in inflammatory pain states, we used a transgenic mouse line
(Mctp5Cre-iDTR) in which MC could be depleted in an inducible manner by administration of diphtheria toxin. Our results show that
ablation ofMC inmalemice did not result in any change inmechanical and thermal hypersensitivity in the CFAmodel of inflammatory
pain. Similarly, edema and temperature triggered by CFA inflammation at the injection site remained identical in MC depleted mice
compared with their littermate controls. In addition, we show that Mctp5Cre-iDTR mice display normal levels of mechanical
hypersensitivity after local injection of nerve growth factor (NGF), a factor well characterised to produce peripheral sensitisation and
for being upregulated upon injury and inflammation. We also demonstrate that NGF treatment in vitro does not lead to an increased
level of tumor necrosis factor-a in bone marrow-derived MC. Furthermore, our qRT-PCR data reveal that MC express negligible
levels of NGF receptors, thereby explaining the lack of response to NGF. Together, our data suggest that MC do not play a direct role
in peripheral sensitisation during inflammatory conditions.
Keywords:Mast cell, Pain, Inflammation, NGF, Neuroimmunology
1. Introduction
The cross-talk between sensory and immune systems is well
recognised. Indeed, the close physical proximity of nociceptors
and immune cells, particularly in peripheral tissues, makes
these systems key subjects of study in both acute and chronic
pain states.34,53,68,71 Though the mechanisms of interaction
are not fully understood, a number of studies demonstrate that
on injury, inflammation triggers the activation of resident and
innate immune cells. This results in the release of proinflam-
matory mediators, culminating in the sensitization of nocicep-
tors, hyperalgesia, and persistent pain.53,68,83 Growing
evidence also suggests that nociceptors in turn can impact
on immune cell function, modulating intracellular properties
and giving rise to some long lasting conditions, such as
arthritis.1,19,24,40,53
Whereas, some populations of immune cells, such as macro-
phages and neutrophils, have an established role in neuropathic
and inflammatory pain,7,8,20,48,56,64,68,76,85 the role of mast cells
(MC) as a mediator of nociceptor sensitisation is much less clear.
Mast cells are known for the presence of granule-like structures
(vesicles), which on activation release a variety of inflammatory
mediators, including chemokines, growth factors, and neuro-
peptides.2,29,37,60 Beyond their well-established role in allergy due
to histamine secretion, MC have also been linked to an array of
chronic pathological conditions such as bladder pain syndrome,
irritable bowel syndrome, and migraine.2,5,16,46,60,61 Furthermore,
a few studies suggest that MC might be involved in acute
peripheral inflammatory pain. It has been shown that thermal and
mechanical hypersensitivity resulting from systemic administration
of nerve growth factor (NGF) could be prevented if MC function
was blocked.47 Since then, other studies using different in-
flammatory models have also proposed a role for MC in hyper-
algesia and allodynia.23,25,69,81,85 Most recently, it was shown that
mice with disrupted c-Kit signalling (a kinase crucial for MC
development10) display altered pain thresholds.38,49 Although
interesting, none of the studies to date conclusively demonstrate
that the effects observed are because of MC ablation, rather than
attributable to off target or compensatory effects.
Herewe set out to test the role ofMC in inflammatory pain using
a novel tool which allows the specific ablation of these cells in an
inducible manner by administration of diphtheria toxin (DTTx). In
this model, DTTx treatment led to depletion of MC in the skin of
Mcpt5-iDTR mice. Ablation of skin MC had no effect on
mechanical hypersensitivity triggered by local injection of NGF.
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Furthermore, our experiments also demonstrate that loss of MC
function has no effect in a long lasting acute model of
inflammatory pain. Taken together, our results suggest that MC
play, if any, only a very minor role in inflammatory pain.
2. Methods
2.1. Transgenic animal model
Mcpt5-iDTR mice26 were obtained from the laboratory of Axel
Roers and maintained homozygous for iDTR and hemizygous for
Mcpt5-Cre on a C57BL/6J background. After initial skin mast cell
depletion studies (Fig. 1A–D), all experiments were conducted in
male mice only. The colony wasmaintained and genotyped by an
independent experimenter, to ensure effective blinding during
any behavioural testing.
2.2. Diphtheria toxin dosing
All mice were 3 to 9 months of age when DTTx treatment
commenced. Mcpt5-iDTR (Mcpt5-Cre; iDTRflox/flox) and control
littermates (iDTRflox/flox) were dosed with an i.p. injection of DTTx
(25 ng/g; Sigma Aldrich) once a week over 4 consecutive weeks.
Before the first injection, animals were injected with H1-antagonist
pyrilamine (5mg/g; PyrilamineMaleate Salt, Sigma Aldrich) to avoid
toxicity because of mast cell degranulation. All experiments were
performed in accordance with the UK Animals (Scientific Proce-
dures) Act 1986 and Local Ethical Committee approval.
2.3. Toluidine blue staining
Mice were deeply anesthetized and transcardially perfused with
4%PFA in PBS. Plantar skinwas collected and postfixed for 1 hour
at room temperature. Following fixation, tissue was immersed in
30% sucrose/PBS (overnight) and then mounted in OCT. Serial
sagittal sections (10 mm thick) were cut with a microtome and
immediately collected onto slides (Superfrost Plus–VWR) coated
with 2% gelatine. Slides were rinsed in water, dipped in 0.5%
toluidine blue solution (pH 4) for 2minutes, washedwith water, and
mounted with DPX. Mosaics of single plane images were captured
on using Axiovision LE Software, Axioskop microscope (Zeiss,
Germany) with a 203 1.3 NA objective. Images (at least 4mosaics
per animal) were analysed by counting positive cells and
normalised by the length of the skin sample.
2.4. Inflammatory pain and nerve growth factor
sensitisation models
To model inflammatory pain, 20 mL complete Freund’s adjuvant
(CFA) (Sigma Aldrich) was injected into the intraplantar area of the
left hind paw. Nerve growth factor was injected using the same
method, at the concentration of 500 ng, dissolved in saline—20mL
final volume per animal.
2.5. Behavioural testing
In all behaviour paradigms, male adult animals (3-9 months) were
used. Weights were monitored and annotated periodically. All the
experiments were performed by an experimenter blind to
genotype.
2.6. Mechanical withdrawal threshold
Mice were placed in a Perspex chamber on a wire mesh floor
and allowed to acclimatise for at least 30 minutes. Withdrawal
Figure 1.Depletion ofmast cells (MC) in theMcpt5-iDTRmousemodel. (A and
C) Representative pictures of hairy skin (dorsal paw) from Mcpt5-iDTR and
control animals (iDTR) stained with toluidine blue, after treatment with
diphtheria toxin (DTTx). Quantification shows that in males (B) MC were
almost entirely depleted in both hairy and glabrous skin (*P # 0.05). By
contrast, Mcpt5-iDTR females (C and D) only showed a mild reduction in the
number of MC in comparison with their littermate controls (iDTR) (P. 0.05) (E)
Behavioural evaluation demonstrates no difference in mechanical withdrawal
threshold between groups before or after DTTx treatment (main effect of
treatment: F (1, 11)5 0.49, P. 0.05; main effect of time: F (1, 11)5 1.38, P.
0.05). Data are means 6 SEM. n 5 3 to 4 per group, 1-tailed Mann–Whitney
test (A and B); n 5 9 (iDTR) and 6 (Mcpt5-iDTR); 2-way repeated measures
ANOVA (E).
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thresholds were determined using the up and down method,15
with a range of von Frey hair forces (0.04-2 g; Touch Test, North
Coast Medical, Inc.). Calibrated hairs were applied to the plantar
surface of the hind paw so the fibre would bend for
approximately 2 seconds or until the animal withdrew its paw.
A 50% paw-withdrawal threshold was calculated as previously
described.15
2.7. Randall–Selitto (paw pressure)
Noxious mechanical threshold was evaluated using mechanical
pressure stimulation based on the Randall–Selitto principle.66 In
brief, animals were lightly restrained, and their hind paw was
placed on the Analgesy-Meter apparatus (7200; Ugo Baseline). A
probe with an increasing force was placed on the dorsal surface
of the hind paw and the nociceptive threshold recorded as the
force at which the animal responded by paw withdrawal. A
maximum of 120 g pressure was applied to prevent any tissue
damage.
2.8. Thermal withdrawal threshold
Thermal threshold of the hind paw was determined using an
incremental hot/cold 20 cm diameter plate (Ugo Baseline) at
a constant set temperature (51˚C and 10˚C, for hot and cold,
respectively). For the noxious hot threshold, animals were
gently placed on the plate, surrounded by a transparent acrylic
cylinder and timed until they flinched, licked, shook the paw, or
jumped. A maximum latency of 30 seconds was set to prevent
blisters or other damage to the plantar skin. For the cold
threshold, animals were gently restrained and their paw was
tested by placing the plantar surface on the plate. The time to
withdraw from the cold surface was recorded. In this test,
a maximum latency of 20 seconds was allowed to prevent any
tissue damage. In both tests, responses were recorded to
a precision of 0.1 second.
2.9. In vivo diphtheria toxin toxicity evaluation
C57/BL6J male mice (3-6 months old) were dosed with an i.p.
injection of DTTx (25 ng/g; Sigma Aldrich) or vehicle (0.9% saline)
once aweek over 4 consecutive weeks. Animals were then tested
on different behaviour paradigms, as described above, 24 hours
after each injection. All the experiments were performed by an
experimenter blind to treatment.
2.10. Purified neuronal culture and in vitro Ca11 imaging
C57/BL6J adult mice were deeply anesthetized and trans-
cardially perfused with 1x PBS. Dorsal root ganglia (DRGs) were
collected and dissociated by enzymatic digestion, followed by
gentle mechanical dissociation.77 Cell suspension was exposed
to biotinylated nonneuronal antibody cocktail (Miltenyi MACS
Neuron Isolation Kit), followed by antibiotin microbeads (Miltenyi
MACS Neuron Isolation Kit). Cells were then run through a LD
exclusion column and placed in a QuadroMACS separator
(Miltenyi Biotech), so only neuronal cells were eluted (.95%
pure neuronal cells generated).77 Neurons were then plated on
matrigel coated coverslips and cultured for 48 hours in F12
medium (5% CO2, 95% O2, at 37˚C).
Following baseline measurements (3 minutes), neurons were
exposed to compound 48/80 at 2 different concentrations, 10
and 100 mg/mL, and imaged for 3 minutes after each exposure.
Cells were washed twice with Ca11 buffer in between
treatments. Regions of interest were selected around cells
and the ratio of the fluorescence intensity at 340/380 nm
excitation was calculated. This fluorescence intensity ratio was
normalised to the baseline ratio. The percentage of responding
cells, after an application of Ca11 buffer and/or compound 48/
80 at the 2 concentrations, was determined visually from
ratiometric traces.
2.11. In vitro stimulation of mast cells
Bone marrow-derived MC(BMMC) were sensitized with mono-
clonal anti-Dinitrophenyl (DNP) immunoglobulinE, (clone SPE-7,
Sigma) at 1 mg/mL overnight. The following day, BMMC were
stimulated with DNP (50 ng/mL) alone or together with various
agonists (UDP-glucose [1 mM], NGF [10 ng/mL]). After a 4 hours
stimulation period, cell culture supernatants were collected, and
cells were lysed for mRNA analysis.
2.12. Enzyme-linked immunospecific assay
Tumor necrosis factor-a (TNFa) cytokine production was
measured in cell culture supernatants by standard enzyme-
linked immunospecific assay (ELISA) using the mouse TNF-a
DuoSet kit (R&D Systems), according to the manufacturer’s
instructions, and read on an ELISA plate reader (Molecular
Devices) set at 450 nm.
2.13. Quantitative real-time polymerase chain reaction
Bone marrow-derived MC RNA was prepared with the RNeasy
Micro kit (Qiagen) and total RNA (500 ng) was converted to cDNA
using the superScript III Reverse Transcriptase kit (Thermo Fisher
Scientific). Rat skin biopsies (glabrous skin) and rat DRGs (used
as positive control) were collected and immediately processed
using the same method as described above. Archival cDNA
extracted from human skin punch biopsies was used to study the
presence of NGF receptors in human skin. Quantitative real-time
polymerase chain reaction (qRT-PCR) was performed in dupli-
cate with a SYBR green master mix (Roche Diagnostics Limited)
and the appropriate gene primers (Sigma) see below. DCts were
calculated in relation to a house keeper gene (GAPDH). Reactions
were run on a Roche Lightcycler 480 PCR machine, and results
analysed by the standard DDCt method. All primers were
checked for their efficiency and specificity.
FCeR1_F: TGTGTACTTGAATGTAACGCAAGA; FCeR1_R:
TGGACTAAGACCATGTCAGCA.
TrkA_F: GAAGAATGTGACGTGCTGGG; TrkA_R: GAAGGAG
ACGCTGACTTGGA.
p75_F: CCGCTGACAACCTCATTCC; p75_R: GGCTGTTGGC
TCCTTGTTTATTT.
Gapdh_F: GGTCCCAGCTTAGGTTCATCA; GAPDH_R: CCA
ATACGGCCAAATCCGTTC.
TrkA_F (Human): CAGGACTTCCAGCGTGAG; TrkA_R (Hu-
man): CGGAGGAAGCGGTTGAG.
p75_F (Human): CTGTGGTTGTGGGCCTTGT; p75_R (Hu-
man): TGGAGTTTTTCTCCCTCTGGTG.
Gapdh_F (Human): GAAGGTGAAGGTCGGAGTCAAC; GAPD
H_R (Human): CAGAGTTAAAAGCAGCCCTGGT.
2.14. Statistical analysis
All data are expressed as mean 6 SEM. For all sets of data,
normality of variance was assessed by a Shapiro–Wilk test. If
samples showed a normal distribution, parametric tests were
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applied; otherwise, nonparametric tests were used. Statistical
analyses were performed using GraphPad Prism Software.
3. Results
We obtained mice expressing a MC protease-Cre fusion
gene (Mcpt5-Cre)26 which had been crossed with
ROSA-floxed-STOP-iDTR mice that contain the sequence of
the human DTTx receptor (DTR) in every cell.11 The resulting
Mctp5Cre-iDTR mice express DTR only in MC, where the Cre
can excise the stop signal. Administration of DTTx then leads
to the conditional ablation of MC while sparing all other
immune cell types.11,26,68 During their first characterisation,
Mcpt5-iDTR mice were shown to be almost completely
depleted of MC in the peritoneal cavity, ear, and back skin
after DTTx administration.26 To further characterise and
determine whether MC could also be ablated in dorsal and
plantar paw skin (hairy and glabrous skin, respectively), we
carried out immunohistochemistry after DTTx treatment (4 i.p.
injections over 4 weeks) in both male and female Mcpt5-iDTR
transgenic mice. Our histology showed a considerable and
significant reduction (;95%) in the number of MC in male
Mcpt5-iDTR mice in relation to their littermate controls (Fig.
1A), demonstrating a successful depletion of MC in both hairy
and glabrous paw skin in transgenic males (Fig. 1B).
Interestingly, in female Mcpt5-iDTR mice the number of MC
only dropped by approximately 40%, a reduction which was
not significant in comparison with Cre negative iDTR
littermates (Fig. 1C, D).
In addition to histological characterisation, we also investi-
gated whether loss of MC in plantar skin causes any behavioural
changes in the Mcpt5-iDTR male mouse model. We found no
alterations in mechanical pain threshold before or after DTTx
(paw-withdrawal responses remained unaffected in a von Frey
test; Fig. 1E). Furthermore, to rule out any possible effects DTTx
could have on sensory neurons in vivo, we tested wildtype mice
which were submitted to DTTx treatment, on different behav-
ioural paradigms. Our results show that DTTx treatment has no
acute (3 hours after first injection), long term (24 hours after first
injection), or chronic effect (4 injections over 4 weeks) on
mechanical (von Frey and Randall–Selitto) or thermal (hot and
cold) thresholds compared with the control (vehicle) group
(Supp. Fig. 1, available online as supplemental digital content at
http://links.lww.com/PAIN/A405). Importantly, mechanical and
thermal thresholds remain unchanged pretreatment and post-
treatment (Supp. Fig. 1A–D, available online as supplemental
digital content at http://links.lww.com/PAIN/A405), except on
the cold plate, where both groups displayed some learning
behaviour (Supp. Fig. 1D, available online as supplemental digital
content at http://links.lww.com/PAIN/A405). Together these
results indicate that the Mcpt5-iDTR male model is a good
system to study the involvement of MC in peripheral sensitisation
and inflammatory pain.
To date, most model systems used to study MC function in
pain present a few drawbacks. For instance, the use of
compound 48/80, known for degranulating and depleting MC,
has been found to have off target effects, also acting directly on
other cell types.17,51,70 To further validate the uniqueness of the
Mcpt5-iDTR model to study MC in pain, and to investigate
whether compound 48/80 has a direct effect in sensory neurons,
we used Ca11 imaging to monitor the neuronal response and
excitability on exposure to different concentrations of compound
48/80. Notably, for these experiments, purified DRG neurons
were used, allowing over 95% cell purity77 and therefore,
excluding any response driven by other nonneuronal cell types.
We found that following baseline recording, at a lower concen-
tration of compound 48/80 (10 mg/mL), approximately 20% of
neurons show an increased excitability almost immediately after
the exposure to compound 48/80 and lasting up to 3 minutes of
recording (Supp. Fig. 2A, B, available online as supplemental
digital content at http://links.lww.com/PAIN/A405). Remarkably,
when the concentration of compound 48/80 was increased (100
mg/mL), almost 70% of the neurons responded to the treatment
(Supp. Fig. 2A, B, available online as supplemental digital
content at http://links.lww.com/PAIN/A405). It cannot be ruled
out that at this high concentration compound 48/80may even be
toxic to neurons, as intracellular Ca11 accumulation remains
constant after several minutes after the application of the drug.
Nevertheless, our data clearly demonstrate that DRG neurons
are capable of responding to compound 48/80, at a dose known
to cause MC degranulation (10 mg/ml)13,33,58,72,75,78 and
independent of the presence of any other cell type. These
findings further demonstrate the unspecificity of compound 48/
80 and emphasise the importance of developing new models,
such as the Mcpt5-iDTR transgenic model, to study MC in
context of pain.
Nerve growth factor is well known for being secreted during
injury and inflammation, leading to a rapid sensitisation of
peripheral nociceptors.41,52,62 Indeed, blockade of NGF signal-
ling has been shown to attenuate allodynia in different models of
persistent pain, and more recently an anti-NGF antibody has
reached phase II and III clinical trials, proving to be a promising
target to alleviate chronic pain.27,28,44,73 Early studies also
suggested that NGF is capable of both activation and pro-
liferation of MC in peripheral tissues.3,4,45,63 We, therefore, used
the NGF sensitisation model6,22,42,43,55,80 to investigate the role
of MC in acute inflammatory pain and nociceptor sensitisation.
As expected, after intraplantar NGF injection, we observed
increased mechanical hypersensitivity in the injected paw of
control animals, as demonstrated by decreased paw-
withdrawal thresholds in the von Frey test (Fig. 2A). Yet, both
control and Mcpt5-iDTR groups showed the same level of
sensitisation triggered by NGF, suggesting that MC do not
potentiate its pronociceptive effects.
Given these unexpected results, and to rule out any possible
compensatory factors, we went on to investigate the direct effect
of NGF on isolated BMMC in vitro. To check the quality and purity
of BMMC, we first analysed our cultures by flow cytometry. We
found that 98% of our cells expressed c-kit, FCeR1, andmast cell
tryptase, confirming successful differentiation of bone marrow
cells into MC after 4 to 6 weeks in culture (Fig. 2B). To test the
effect of NGF onMC activation, we sensitised the cells using DNP
and immunoglobulin E (IgE) and treated them with NGF (4 hours,
10 ng/mL). UDP-Glucose was used as positive control, as it is
known to stimulate and induce production of TNFa by MC.31,36
Nerve growth factor did not induce increased secretion of TNFa
when compared with DNP alone, as measured by ELISA (Fig.
2C). To clarify these findings, we checked the expression levels of
the 2 NGF receptors—TrkA and p75—in BMMC via qRT-PCR.
Our data demonstrate that basal levels of both NGF receptors in
MCwere negligible (Fig. 2D). After treatment with NGF, there was
a very moderate increase in the levels of TrkA and p75 mRNA in
MC (Fig. 2D). Nevertheless, levels of NGF receptors were
negligible when compared with basal levels of FCeR1 (Fig. 2D).
Similarly, levels of NGF receptors were also negligible in peritoneal
MC (data not shown). Overall, our results demonstrate that NGF
treatment has no effect on MC as these cells do not express NGF
receptors.
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To further explore the link between NGF and MC, and the
relevance of our findings to other systems, we went on to
investigatewhetherNGF receptors are expressed in rat andhuman
MC. Our qRT-PCR results indicate that, similarly to mice, NGF
receptors are not present in the MC of rats or humans, as levels of
TrkA and p75 were negligible in the skin samples analysed (Supp.
Fig. 3A, B, available online as supplemental digital content at http://
links.lww.com/PAIN/A405). These results reinforce our previous
findings indicating that MC do not express NGF receptors.
To rule out the possibility that our stimulus (NGF) might have
been too specific or mild to lead toMC recruitment and activation,
we set out to study a much stronger proinflammatory insult. For
these experiments we used the well-characterised, CFA model,
which induces chronic inflammation and hypersensitivity at the
injection site, as well as the recruitment and activation of
MC.14,50,57,59,67,82 Our experiments demonstrate that depletion
of MC, using the Mcpt5-iDTR model, had no impact on
mechanical and thermal hypersensitivity thresholds 24 hours
after intraplantar injection of CFA. No significant differences
emerged between MC depleted mice and their littermates on von
Frey, Randall–Selitto, hot or cold plate tests (Fig. 3A–D). Crucially,
when evaluating later stages after the acute phase (3 and 4 days
after CFA injection), we still did not observe any change in
mechanical or thermal hyperalgesia between the 2 groups of
mice (Fig. 3A–D). Furthermore, edema (paw thickness) and
temperature triggered by CFA inflammation was consistent
between the groups (Fig. 4A, B), both in acute (24 hours) and
longer-term inflammation (3 days). Together, our data indicate
that MC contribute little to the sensitisation of peripheral
nociceptors during CFA-mediated inflammation.
4. Discussion
In this study, we have analysed the role of MC in the sensitisation
of peripheral nociceptors during acute inflammation. Our
evidence indicates that MC appear to not be essential for this
process; in the Mcpt5-iDTR mouse model, where almost
complete depletion of MC in glabrous skin was achieved, animals
still displayed normal levels of mechanical hypersensitisation after
local injection of NGF. This was further supported by our in vitro
studies, demonstrating that NGF alone had no effect on the level
of TNFa secreted byMC. Similarly, when challengedwith a strong
inflammatory stimulus (CFA), Mcpt5-iDTRmice still presented the
same levels of mechanical and thermal hyperalgesia as their
control littermates, both in acute and longer-term phases (3-4
days) of inflammation. Sensitisation of peripheral nociceptors
during inflammation is, therefore, likely to be mediated and
potentiated by immune cells other than MC.
Evidence for the contribution of MC to acute inflammatory
sensitisation of nociceptors is not strong. Previous studies
have implied that loss of MC function could be implicated in
pain, and induction of this process could, therefore, represent
a potential target for alleviating acute peripheral neuronal
sensitisation23,25,38,47,49,69,81,85. However, most of these
Figure 2.Nerve growth factor (NGF) treatment has no effect onmast cells (MC). (A) Intraplantar injection of NGF shows a similar decrease in mechanical threshold
in both groups of animals, 1 hour after injection and 3.5 hours after the injection (F(2,36) 5 23.40; P , 0.001). Data from baseline and contralateral paw
demonstrates no underlying differences between MC depleted animals and control littermates (F(1,18) 5 0.05; P . 0.05). (B) FACS dot plots showing gating
strategy for bone-derived MC. (C) Graph showing the quantification of tumor necrosis factor-a release (enzyme-linked immunospecific assay [ELISA]) from Bone
marrow-derivedMC (BMMC) after treatment with NGF, in comparisonwith basal levels (dinitrophenyl [DNP]) and treatment with UDP-Glucose (positive control). (D)
qRT-PCR for NGF receptors on RNA extracted from BMMC (n5 3 experiments), before (DNP) and after treatment with NGF (TrkA: black bars; p75: gray bars), in
comparison with basal levels of FCeR1 (white bar). Data are means 6 SEM. n 5 12 (iDTR) and 8 (Mcpt5-iDTR); 2-way ANOVA repeated measures (A).
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studies suffered from many confounding factors due to their
experimental design. For instance, compound 48/80, which is
broadly used to acutely degranulate and deplete MC, has been
found to have a profound impact on other immune cells, including
neutrophils and eosinophils17,51 and directly affects sensory
neuron excitability, as shown in this study, and previously
suggested by Schemann et al.70 Furthermore, interpretation from
studies usingmore refined techniques such asMC transgenic lines
have equally proven tobe ambiguous, in particular thoseusing c-kit
transgenics. Recent findings have shown that constitutive
disruption of c-kit signalling has significant consequences for the
function and number of many immune cell types other than MC,
such as erythrocytes and neutrophils.30,39 Crucially, beyond the
immune system, it has been shown that c-kit is expressed in spinal
cord neurons and nociceptors,54,74 a result which is further
supported by recent RNA sequencing data.77,79
To overcome these limitations, in our study we used an
established transgenic line (Mcpt5-iDTR), where MC deficiency can
Figure 3. Loss of mast cells (MC) does not reduce peripheral sensitisation during inflammation. (A) Paw withdrawal on the von Frey test showed a decreased
mechanical threshold in both groups of animals after intraplantar complete Freund’s adjuvant (CFA) injection (F(9,66)5 2.94; P# 0.005), 24 hours, 72 hours and 4
days after injection (F(3,66)5 12.30; P, 0.001). Baseline and contralateral paw-withdrawal thresholds demonstrated no underlying differences between groups
(F(3,22)5 2.45; P. 0.05). (B) Paw withdrawal on the Randall–Selitto test further demonstrated a sensitisation to a noxious mechanical stimuli after CFA injection
(F(6,52)5 6.10; P, 0.001), both 24 and 72 hours after injection (F(2,52)5 25.41; P, 0.001). (C) CFA treatment equally changes thermal hypersensitivity on the hot
plate (F(2,26)5 4.47, P, 0.05) and cold plate (F(2,26)5 25.41; P, 0.001) (D). Data aremeans6SEM. n5 9 (iDTR) and 6 (Mcpt5-iDTR); 2-Way repeatedmeasures
ANOVA.
Figure 4. Depletion of mast cells has no impact on gross physiological changes triggered by inflammation. (A) Measuring of edema after complete Freund’s
adjuvant (CFA) injection shows a significant swelling in comparison with baseline (F(9,78)5 75.47;P, 0.001), but no difference between groups (F(1,13)5 1.69;P.
0.05). (B) Similarly, paw temperature in the injected area increased after inflammation (F(2,52)5 74.22; P, 0.001), but was very similar in iDTR and Mcpt5-iDTR
animals (F(26,52) 5 0.56; P . 0.05). Data are means 6 SEM. n 5 9 (iDTR) and 6 (Mcpt5-iDTR); 2-way repeated measures ANOVA.
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be induced by administration of DTTx11,26 and has no impact on
other immunecell populations.26,39Wehaveshownalmost complete
depletion of MC in the paw skin of this Mcpt5-iDTR model, and the
reduction in the number of cells was comparable in size with that
reported in other tissues in this same transgenic system.26
We also found sex differences when attempting to depleteMC,
with MC counts in female mice remaining almost unaffected by
DTTx treatment. It is likely that this observation is because of the
role that female hormones play in MC behaviour, affecting their
number and degranulation, as previously reported.9,35,84 These
findings mean that we cannot comment on the role of MC in
female mice because of the specifics of our experimental design.
More importantly, they also imply that particular care has to be
taken when designing future investigations into the role of MC in
pain, particularly in females.
Acute NGF response, MC and hypersensitisation: a cross-talk
pathway?NGF has awell-established role in the adult nociceptive
system, mediating and modulating pain, as well as causing
changes in gene expression, particularly in persistent pain
states.41,52,65 Acute NGF treatment leads to mechanical and
thermal hyperalgesia,6,22,42,43,55,80 an effect that was believed to
be directly linked to MC activation.3,4,45,47,63,69,81 Surprisingly,
our results revealed that depletion of MC in vivo does not reduce
acute NGF-induced peripheral sensitisation. In addition, our in
vitro experiments further supplemented these findings and
demonstrated that NGF does not activate MC. We were also
able to show that MC express neither of the 2 NGF receptors,
TrkA or p75, explaining their lack of response on exposure to
NGF. Importantly, our results are in line with recent RNA-seq data
which show that bone marrow-derived, peritoneal and intestinal
MC have none or negligible levels of TrkA and p75.12,18 In
addition, we also show similar results in samples from rat and
human skin, with our data once more replicating previously
published RNA-seq data.21 Although a dilution effect cannot be
excluded when studyingMC in skin, the overwhelmingmajority of
recent expression data support our conclusion that MC play an
inconsequential role in NGF-mediated nociceptor sensitisation,
primarily because they lack NGF receptors. Naturally, it cannot be
ruled out that more chronic inflammatory conditions eventually
upregulate NGF receptors on MC, rendering them directly
sensitive to this particular pain mediator. Or indeed, it could be
that long-term exposure to NGF has an indirect effect on MC
function, increasing other important inflammatory mediators in
these cells that then go on to impact sensory neurons or other
immune cell types.
Do MC play a role in the inflammatory response? Our results
demonstrate that MC have no evident immediate role in NGF or
CFA triggered sensitisation, including its more persistent phases.
These results are supported by a recent study which demon-
strates that CFA-induction and maintenance of mechanical and
thermal hyperalgesia are primarily dependent on specific
populations of myeloid cells, particularly macrophages.32 These
findings imply that pursuingMCas a target to alleviatemechanical
and thermal allodynia, as well as to attenuate edema and other
physiological changes that arise immediately after inflammation,
might not be themost appropriate approach to tackle pain during
inflammation. Although we show no obvious function for MC at
early tomid-term stages of sensitisation, we speculate that during
long-term inflammatory conditions MC may get primed to
potentiate inflammatory responses, and therefore, may have
a potential impact on nociceptors in a chronic pain scenario.
According to this view, sensitisation would occur as a result of
more complex transcriptional and molecular alterations. Future
studies exploring whether MC can directly sensitise afferents
during long periods of inflammation will be necessary to fully
understand their role–if any–in more persistent pain conditions.
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